News

Transcend Therapeutics' TSND-201 gains FDA Breakthrough Therapy designation, offering new hope for rapid PTSD treatment with promising clinical trial results.

Actual LLT use was significantly lower than the proportion of guideline-eligible patients for statins, ezetimibe, and PCSK9i.

This announcement highlights Pelthos Therapeutics’ launch of berdazimer (ZELSUVMI) topical gel 10.3% for molluscum contagiosum.

Lonsberry recommends alternative approaches to manage postoperative pain, balancing the need for relief against the risk of addiction and death.

New data from a UMichigan survey found that 8% of preventative aspirin users had not even discussed their use with any health care provider.

The initial batch of published CRLs are associated with since-approved applications in an effort to increase transparency and provide insight into the decision-making process.

This study highlights the rate of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use for heart failure within US ambulatory cardiovascular care settings.

Discover how structured routines and exercise enhance mental health for those with bipolar disorder, fostering stability, and community support.

The prespecified analysis of FINEARTS-HF found finerenone’s impact on HF events, cardiovascular death, and symptoms was not impacted by frailty.

Whitley speaks to the plethora of available biologics, the choice paralysis that can accompany the wide range of options, and the future of the industry.

Drs. Richman and Wartman discuss the benefits of using predictive and diagnostic AI, while cautioning about the implicit risks of overreliance on early, imperfect technology.

These ADHAND trial data highlight the results of tralokinumab in those with atopic dermatitis on the hands who are candidates for systemic therapy.

Findings highlight the ongoing burden of generalized pustular psoriasis and suggest patients may benefit from targeted biologic therapies like the FDA-approved spesolimab.

The first half of 2025 recap for nephrology spotlights renal FDA action, ERA 2025 Congress coverage, and updates in xenotransplantation.

In ARRECTOR, patients reported symptom relief and improved quality of life as early as week 2, with strong tolerability and safety through week 8.

This clinical episode of Skin of Color Savvy features a discussion on UV safety and photo protection in patients with skin of color.

Long-acting injectables improve outcomes in schizophrenia, yet remain underutilized, highlighting the need for earlier, proactive conversations in care.

The first half of 2025 recap for gastroenterology spotlights GI FDA approvals, clinical trial data, and new guidance on bowel preparation for colonoscopy.

Based on reduced FOXP3+ expression in patients, investigators have drawn a strong correlation between MetS due to psoriasis and immune dysregulation.

New research reveals significant links between alopecia areata and mental health issues, emphasizing the need for comprehensive care in affected individuals.

Veeral Sheth, MD, is joined by the director of marketing of eSight to discuss the 5th generation eSight Go, a device to enhance central vision functions in patients with a variety of eye diseases.

Phase 3 trials have shown low rates of serious adverse events with ruxolitinib cream in pediatric and adult patients with atopic dermatitis and non-segmental vitiligo.

Findings suggest pediatric patients with guttate or inverse psoriasis may warrant evaluation for pharyngeal or anogenital bacterial infections.

Gastrointestinal disorders, atopic conditions, and other diseases may have similar or shared pathogenetic mechanisms with AA, based on recent research.

Overall, older treatment strategies such as methotrexate and phototherapy still led the way for cost-effectiveness.

In this session at SDPA, Griffith and Sebat review clinically relevant articles from the prior 12 months from the top dermatology journals.

Positive topline results showed patients who received 2 scheduled rilparencel injections experienced significant eGFR slope decline improvement.